First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease – TauRx Publishes Positive Results of Phase II Clinical Trial in the Journal of Alzheimer’s Disease

ABERDEEN, Scotland and SINGAPORE, 20 January 2015 – The Journal of Alzheimer’s Disease has published today the results of the first clinical trial of a Tau Aggregation Inhibitor (TAI) in Alzheimer’s disease (AD). This Phase II clinical trial, conducted by TauRx Therapeutics Ltd (a Singapore incorporated spinout from the University of Aberdeen), provided the basis and rationale for subsequent Phase III clinical trials of a TAI in AD currently in progress.

Read more here.